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Background: To provide information on the burden of bronchiectasis in England and Wales, we
have examined trends in mortality using death certificate data available from the Office of
National Statistics.
Methods: We extracted data on deaths due to non-cystic fibrosis bronchiectasis for 2001e2007
inclusive and stratified deaths by sex and age group. We used Poisson regression to compare
mortality rates.
Results: Between 2001 and 2007, 5745 bronchiectasis related deaths were registered in
England and Wales. When standardized to the 2007 population, this showed a rise in absolute
numbers from 797 (2001) to 908 (2007). Statistical analyses suggested that the mortality rate is
currently increasing at 3%/year (p < 0.001). Mortality rates were similar between men and
women but there was a strong statistical interaction between age group and year
(p < 0.001) Rates were increasing in the two oldest age groups but falling in the three youngest
groups.
Discussion: Currently just under 1000 people die from bronchiectasis each year in England and
Wales. We found the number of deaths to be increasing at 3% per year. Although overall
mortality was increasing, rates were increasing in older groups but falling in the younger
groups.
These mortality rates may underestimate the burden of disease from bronchiectasis as lack
of knowledge about the disease may lead to underreporting. These are also mortality rather
than incidence data and may reflect improvements in treatment.
Bronchiectasis therefore remains a significant concern. Clinical provision will potentially
need to increase in order to care for this patient group.
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Bronchiectasis is a common problem in respiratory clinics
but historically has received little research interest. With
the introduction of better antibiotic therapy, particularly in
early life, the disease has traditionally been thought to be
in decline.
However, there are no data to support this view and
there has previously been little information on the burden
of disease or how it is changing. Recently, Kelly MG et al
found that 410 patients with bronchiectasis had attended
the respiratory clinic in a 6 month period in a department
run by 4 respiratory physicians. The 100 randomly chosen
studied patients made 321 clinic attendances, with 39
attending on 4 or more occasions.1
Using mortality data is an established method of looking
at disease burden and has historically been used in other
disease processes. For example, Hubbard et al. used
mortality data to look at trends in mortality in cryptogenic
fibrosing alveolitis in seven countries in 1996.2
Therefore, in this study we have examined trends in
bronchiectasis mortality in England and Wales by gender
and by age group using data available from the Office of
National Statistics (ONS), in an attempt to quantify some of
the burden of disease due to bronchiectasis and determine
whether this is changing over time.Figure 1 Total bronchiectasis mortality rate (standardized
to 2007 population).Methods
Annual mortality statistics are published by the Office of
National Statistics and are freely available. They present
mortality statistics on the cause of deaths registered in
England and Wales in a given year. Details are collected
when a death is certified and then registered and are
classified by selected information, which includes age and
sex. We extracted data on deaths registered due to non-
cystic fibrosis bronchiectasis in England and Wales3e9 for
years 2001e2007 inclusive. These dates were chosen
because 2001 was the first year in which the ICD 10
(International Classification of Disease) code was used to
identify cause of death. In the ICD 10, code J47 identifies
bronchiectasis related deaths and excludes deaths due to
congenital bronchiectasis. Prior to 2001, the ICD 9 code
(494) included all bronchiectasis deaths.
We stratified bronchiectasis related deaths by sex and
age group. Age groups used were as follows:0e14; 15e44;
45e64; 65e74; 75 and over. These age groups band
together narrower groups used by the ONS so that the data
can easily be transferred but a broader age range used. We
also recorded the total population for each sex and age
group for each year. The data were standardized to the
2007 population. Standardisation uses the age group and
sex specific disease rates from each year and applies them
to the 2007 population. This tells us the number of deaths
that would be expected in each year if the make up of the
population in that year was the same as the population in
2007. Therefore this allows us to compare death rates
across different years (ie looking for a trend), whilst
allowing for differences in sex and age structures of the
population at different times.The interpolated mean age of death from bronchiectasis
in each year group was also calculated, using the number of
deaths in each age group and the mid point of that age
range. Using the idea that all patients in that age group
died at the age of the mid point of the age range allowed us
to calculate an interpolated mean age of death for each
year. The upper age limit for the final group is assumed to
be 95 as the ONS statistics use the range 95 and over for
that group.
For our statistical analyses to compared mortality rates,
we used Poisson regression (Stata version 7.0). For these
analyses we used the stratum specific deaths as the
numerator and stratum specific population for the denom-
inator. Initially we looked at the effects of sex, age and
year in a series of univariate analyses, and then fitted
a multivariate model with all three variables simulta-
neously. Finally we looked for evidence of interaction
between year and both sex and age group using multipli-
cative interaction terms.
Results
Between 2001 and 2007, 5745 deaths due to bronchiectasis
were registered in England and Wales, rising from 727
deaths in 2001 to 908 deaths in 2007. The male: female
ratio was 1: 1.34. The overall mean age of death from
bronchiectasis was 74.4 years, which has risen from 72.8 in
2001 to 75.7 in 2007.
When standardized to the 2007 population (to allow for
differences in sex and age structures of the population),
the number of deaths is 797 in 2001 and 908 in 2007. This
represents a total of 1.68 deaths from bronchiectasis per
100,000 population in 2007, which is 0.18% of all deaths.
Fig. 1 shows the bronchiectasis mortality rate for each year,
when standardized to the 2007 population, as described
above, and also the division by sex.
The results of our univariate analyses suggested that the
crude death rates from bronchiectasis were higher in
females and older people and had increased year on year
Table 1 Results of univariate and multivariate analyses.
Variable Number
of deaths
Total
population
Univariate
Rate Ratio
95% CI P value Mutually
adjusted
rate ratio
95% CI P value
Sex Female 3293 189628600 1.00 1.00
Male 2452 181942300 0.78 0.74 to 0.82 <0.001 1.03 0.97 to 1.08 0.10
Age Group 0e14 12 214862900 1.00 1.00
15e44 80 154231900 2.92 1.59 to 5.35 2.91 1.59 to 5.35
45e64 831 90 261 100 51.79 29.29 to 91.57 51.71 29.25 to 91.42
65e74 1375 31 012 100 249.42 141.30 to 440.27 249.40 141.29 to 440.24
75þ 3447 28 560 800 678.93 385.19 to 1196.67 <0.001 679.99 385.78 to 1198.59 <0.001
Year 2001 727 52 084 800 1.00 1.00
2002 710 52 455 300 0.97 0.87 to 1.08 0.97 0.87 to 1.07
2003 856 52 793 600 1.16 1.05 to 1.28 1.16 1.05 to 1.28
2004 824 53 046 400 1.11 1.01 to 1.23 1.10 1.00 to 1.22
2005 835 53 390 200 1.12 1.01 to 1.24 1.11 1.00 to 1.22
2006 885 53 728 700 1.18 1.07 to 1.30 1.16 1.05 to 1.28
2007 908 54 071 900 1.20 1.09 to 1.33 <0.001 1.18 1.07 to 1.30 <0.001
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of year was linear and so we also modelled year as
a continuous variable and this analysis suggested that the
mortality rate from bronchiectasis is currently increasing at
the rate of 3% per year (univariate rate ratio 1.03, 95%
confidence interval 1.02e1.05, p < 0.001).
However, the results of the multivariate analyses
(allowing for the effects of age and year) show that the
mortality rates are actually very similar between men and
women, whilst the effects of age group and year were
virtually unchanged. The adjusted year on year increase in
bronchiectasis mortality rate was again 3% (adjusted rate
ratio 1.03, 95% confidence interval 1.02e1.04, p < 0.001).
We found evidence of a strong statistical interactionFigure 2 Male bronchiectasis mortality rate (standardbetween age group and year (p < 0.001) such that the
mortality rates were increasing over time in the two oldest
age groups but falling in the three youngest age groups.
Figs. 2 and 3 show the standardized mortality by age group
in males and females respectively. There was no evidence
of interaction between sex and year.
Discussion
Wefound that the total numberof deaths frombronchiectasis
in England and Wales is increasing at a rate of approximately
3% per year to 908 in 2007 (1.68 per 100,000 population). This
compares, for example to amortality rate (2007) in asthmaofized to 2007 population) with division by age group.
Figure 3 Female bronchiectasis mortality rate (standardized to 2007 population) with division by age group.
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are similar between men and women but have risen in older
age groups and fallen in younger groups.
Our data show trends in bronchiectasis mortality with
time. We have been able to use univariate and multivariate
analysis to look at the effects of sex, age and year on all
bronchiectasis deaths between 2001 and 2007.
Mortality rates in bronchiectasis may well in fact under-
estimate the problem. The information is, of course,
dependent on the correct reporting of the cause of death and
lack of knowledge about bronchiectasis may well lead to
underreporting it as the cause of death. Also there may have
been some diagnostic transfer to cystic fibrosis, particularly
among the younger groups, therefore affecting themortality
rate in these groups. These are also mortality rather than
incidence data, and therefore may reflect recent improve-
ment in awareness and treatment of bronchiectasis.
The increase in mortality rate could be ascribed to
increased recognition and reporting, or to the ready avail-
ability of CT, now commonly used for diagnosis. However, if
this were the case, an increase in mortality would be expec-
ted in all age groups, which is not the case with our study.
There is little other data showing mortality in bronchiec-
tasis in England and Wales. New Zealand figures published in
1995 (using data obtained from the National Health Statistics
Center) suggested a very high rate in the Maori population,
with an annualmortality of 10 per 100 000 population in those
aged between 35 and 29 years. High rates of hospitalization
were also found, with between 30 and 50/100,000 per year
being attributable to bronchiectasis.10 Another New Zealand
study found that 307 admissions occurred in a one year period
in 152 patients studied.11 Dupont et al. found a 1 year
mortality of 40% in patients with bronchiectasis following an
ICU stay. Age>65 and prior use of Long TermOxygen Therapy
were associated with reduced survival.12 A Finnish study
found prognosis in bronchiectasis to be better than for COPDin matched patients, but worse than for asthma.13 A recent
European study showed 4 year survival of 58% in a prospective
study of 98 outpatients with bronchiectasis.14 Another UK
study found mortality from bronchiectasis to be 68% at
12 years. Factors independently associated with mortality
were age, St George’s Respiratory Questionnaire activity
score, infection with Pseudomonas aeruginosa, Total Lung
Capacity (TLC), Residual volume/TLC and transfer factor
coefficient.15
Our study suggests that contrary to traditional views,
bronchiectasis is still a significant problem, with increasing,
rather than decreasing mortality. Whilst the increase is in
older age groups, and may eventually start to decrease with
time, for the moment it is still of significant concern and
clinical provision for patients with bronchiectasis will need
to continue and potentially increase.Conflict of interest
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